Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.30 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.30 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633231 | 0.77 | UHRF1 (0.43) | UHRF1DYRK1AROCK2ROCK1PSEN1 | |
| SCHEMBL11075725 | 0.75 | UHRF1 (0.50) | UHRF1DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL17198732 | 0.74 | UHRF1 (0.48) | UHRF1DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL19846691 | 0.74 | UHRF1 (0.48) | UHRF1DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL20247131 | 0.72 | UHRF1 (0.46) | UHRF1DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL14041762 | 0.72 | UHRF1 (0.46) | UHRF1DYRK1AROCK2ROCK1PSEN1 | |
| SCHEMBL20715407 | 0.70 | KDM4E (0.45) | — | |
| SCHEMBL31639163 | 0.69 | BLM (0.48) | UHRF1 | |
| SCHEMBL14585859 | 0.69 | KMT2A (0.42) | UHRF1DYRK1AROCK2ROCK1PSEN1 | |
| SCHEMBL30490644 | 0.69 | UHRF1 (0.52) | UHRF1DYRK1APSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370786-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370786-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLB1 | UHRF1 4748/4885DYRK1A 3405/4885ROCK2 3463/4885 |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | UHRF1 4346/4885DYRK1A 4330/4885ROCK2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.